PBAC's latest decision on Deferasirox: Recommended (2020). Considered for Chronic iron overload due to disorders of haemopoiesis, including transfusion-dependent malignant and non-malignant disorders of erythropoiesis, and non-transfusion-dependent thalassaemia.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2006
Submissions
5
2006 → 2020
Eligible population
Patients with chronic iron overload due to disorders of haemopoiesis: transfusion-dependent malignant disorders of haemopoiesis with median life expectancy exceeding five years; transfusion-dependent non-malignant disorders of erythropoiesis; and non-transfusion-dependent thalassaemia.
Cost-minimisation analysis; no ICER calculated as the submission was on a cost-minimisation basis with Jadenu as comparator.
ICER (historical)
$15k/QALY–$45k/QALY across 2 submissions (2006–2014) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Risk sharing
Risk-sharing arrangement in place — Special Pricing Arrangements (SPA) apply to the listing, as noted in the administrative advice sections for each restriction.